Wedbush reiterated their outperform rating on shares of Scholar Rock (NASDAQ:SRRK – Free Report) in a report issued on ...

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.

A Prescription Drug User Fee Act (PDUFA) target action date for apitegromab has been set for Sept. 22, 2025.

Apitegromab is an investigational treatment aimed at improving motor function for people living with spinal muscular atrophy. Scholar Rock said it has also submitted and received validation for its ...

Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

History buffs dove into thousands of pages of government records released online this week, hoping for new nuggets about ...

Data from the SAPPHIRE study formed the basis of Scholar Rock's U.S. Food and Drug Administration request to approve ...

More than 50 wildfires burned across the state on Wednesday afternoon, causing damage to homes and businesses in Little Rock ...

When medieval scholars sought to understand the nature of angels, they unwittingly laid the foundations of modern physics ...

Scholar Rock’s spinal muscular atrophy (SMA) therapy has shown benefit in muscle function in children under 12 in a pivotal ...

In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Scholar Rock Holding (SRRK – Research ...